Skip to content

Rational design of hybrid hydrazide-hydrazone/thiourea derivatives as potential VEGFR-2 targeting anticancer agents: synthesis, biological evaluation, and mechanistic insights into anticancer activity.

Sep 2026 · Bioorganic chemistry (Print) · Vol 182, pp. 110531 · 0 citations · 57 references
Medicine

TL;DR

Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways.

Abstract

The development of novel anticancer agents capable of modulating pathways associated with tumor progression remains a critical strategy, particularly for aggressive breast cancer subtypes such as triple-negative breast cancer (TNBC). In this study, a new series of hydrazide-hydrazone/thiourea derivatives (MIH-31-46) was rationally designed, synthesized, and evaluated as potential anticancer agents targeting vascular endothelial growth factor receptor-2 (VEGFR-2). Structural characterization was performed using 1H NMR, 13C NMR, and HR-MS. The antiproliferative activities of the synthesized derivatives were assessed against MCF-7 and MDA-MB-231 breast cancer cell lines, along with non-cancerous L929 cells. Several compounds exhibited moderate cytotoxicity, with MIH-36 emerging as the most promising candidate, demonstrating dual activity against both cancer cell lines and improved selectivity. Functional assays revealed that MIH-36 significantly inhibited cell migration and induced apoptosis in both models. Mechanistic investigations revealed increased VEGFR-2 mRNA expression, accompanied by reduced surface VEGFR-2 levels, suggesting possible interference with VEGFR-2-associated signaling through feedback regulation and receptor internalization. Molecular docking and molecular dynamics simulations supported the experimental findings, indicating strong binding affinity of MIH-36, MIH-38, and MIH-44 toward VEGFR-2, particularly in its inactive (DFG-out) conformation, suggesting a potential type II inhibitor-like binding profile. Stable interactions with key residues, such as Cys919, Glu885, and Asp1046, along with favorable binding free-energy profiles, further support their potential as VEGFR-2-targeting compounds. Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways. These findings provide a valuable framework for further optimization and development of hydrazide-hydrazone/thiourea-based VEGFR-2-targeted therapeutics.

View source

Similar papers

Sep 2026

Cyanopyridine-based derivatives as potent anticancer agents: Integrating in silico analysis and in vitro biological targeting of the EGFR/AKT/MAPK Signaling Cascade.

The combined results underscore the promise of the cyanopyridine scaffold as a framework for developing selective multi-target anticancer medicines and identify compound 2b as the most selective and potent derivative in the series.

Shimaa M. Alhamaky, Marwa S. A. Hassan, Eman M. Ahmed et al. · 0 citations
Open access Sep 2026

Biological Investigation of Novel Pyrazole-Based Anticancer Scaffolds: A Trinity of Synthetic Methodologies on Computational Assessment of IC50 Against Human Cancer Cell Lines MCF-7, MDA-MB and HeLa.

Aurora kinase A (AURKA) is a key regulator of mitotic progression and is frequently overexpressed in human malignancies, making it an attractive therapeutic target for the development of targeted anticancer agents. The present study aimed to design and synthesize sixteen novel pyrazole derivatives (Pz-01 to Pz-16) as p...

P. Kumari, Anandkumar Tengli · 0 citations
Sep 2026

Design, synthesis, mechanistic evaluation, and in silico study of pyrimidine-coumarin hybrids as promising anticancer agents.

Breast and lung cancers remain among the leading causes of cancer-related mortality worldwide, highlighting the urgent need for the development of effective targeted therapeutics. In this study, a series of novel pyrimidine-coumarin hybrid derivatives were rationally designed, synthesized, and biologically evaluated fo...

R. Vinay, S. Alegaon, H. S. Basavaraja et al. · 0 citations
Oct 2026

Pyridine-core scaffolds suppress A549 lung cancer cell progression: Evaluation of the antiproliferative activity, apoptosis, ROS generation, clonogenic suppression, and EGFR expression.

Targeting the epidermal growth factor receptor (EGFR) remains a proven strategy for the treatment of lung adenocarcinoma; however, acquired drug resistance and suboptimal long-term efficacy of the currently available EGFR inhibitors spurred the pursuit of new EGFR-targeted molecules. Hence, a series of pyridine-cored d...

K. SachinKumar, N. Satyanarayan, L. Vedavi et al. · 0 citations
Open access Sep 2026

Design, synthesis, and molecular modeling of quinoline-linked diphenylpyrazoles as multitarget EGFR, VEGFR-2, and COX-2 inhibitors with anticancer, anti-inflammatory and apoptosis-inducing properties.

A new series of quinoline-diphenylpyrazole hybrids were rationally designed, synthesized, and biologically evaluated as potential EGFR/VEGFR-2/COX-2 inhibitors, supporting the proposed hybrid design strategy.

Abdelrahman Hamdi, Mohamed R. Elnagar, M. Hussein et al. · 0 citations
Open access Sep 2026

Quinoline clubbed triazole hybrids as VEGFR-2 targeted anticancer agents: synthesis, molecular modeling, and biological evaluation

Findings highlight quinoline–triazole hybrid SVI08 as a preliminary lead to the further optimization as a VEGFR-2-targeted anticancer agents as well as acceptable ADMET properties and good in vivo tolerability up to 50 mg/kg.

Divyanshi Thakur, Mangaldip Ghosh, Shivam Nag et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.